The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models

Co-overexpression of Met and Hepatocyte Growth Factor Promotes Systemic Metastasis in NCI-H460 Non-Small Cell Lung Carcinoma Cells

(2015) Roya Navab et al.   NEOPLASIA

Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition

(2013) R. Katayama et al.   CANCER RESEARCH

EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors

(2013) F. Bladt et al.   CLINICAL CANCER RESEARCH

Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET

(2013) C. Basilico et al.   CLINICAL CANCER RESEARCH

Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma

(2013) L. Goyal et al.   CLINICAL CANCER RESEARCH

HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma

(2013) Shugaku Takeda et al.   JOURNAL OF CLINICAL INVESTIGATION

Linking MLL and the HGF-MET signaling pathway in liver cancer

(2013) Jens U. Marquardt et al.   JOURNAL OF CLINICAL INVESTIGATION

Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma

(2013) Jie Sheng Chu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Epigenetic Upregulation of HGF and c-Met Drives Metastasis in Hepatocellular Carcinoma

(2013) Olorunseun O. Ogunwobi et al.   PLoS One

Cell-Autonomous and Non-Cell-Autonomous Mechanisms of HGF/MET-Driven Resistance to Targeted Therapies: From Basic Research to a Clinical Perspective

(2013) S. Corso et al.   Cancer Discovery

Progress in cancer therapy targeting c-Met signaling pathway

(2012) Kyung Hee Jung et al.   ARCHIVES OF PHARMACAL RESEARCH

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

(2012) David R. Spigel et al.   Clinical Lung Cancer

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

(2012) Armando Santoro et al.   LANCET ONCOLOGY

c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma

(2011) Hanning You et al.   HEPATOLOGY

Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma

(2011) Jiliang Qiu et al.   Journal of Translational Medicine

Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma

(2011) Q. Xie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth

(2011) Yoshinori Inagaki et al.   BioScience Trends

A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer

(2011) A. Bertotti et al.   Cancer Discovery

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

(2010) N. Munshi et al.   MOLECULAR CANCER THERAPEUTICS

Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

(2009) J. P. Eder et al.   CLINICAL CANCER RESEARCH

Down-Regulation of c-Met Expression Inhibits Human HCC Cells Growth and Invasion by RNA Interference

(2009) Bin Xie et al.   JOURNAL OF SURGICAL RESEARCH

The Met tyrosine kinase receptor in development and cancer

(2008) Alessandra Gentile et al.   CANCER AND METASTASIS REVIEWS

Direct In Vivo Xenograft Tumor Model for Predicting Chemotherapeutic Drug Response in Cancer Patients

(2008) B Rubio-Viqueira et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS